WallStSmart
ANVS

Annovis Bio Inc

NYSE: ANVS · HEALTHCARE · BIOTECHNOLOGY

$2.28
-5.03% today

Updated 2026-06-05

Market cap
$78.70M
P/E ratio
P/S ratio
EPS (TTM)
$-1.71
Dividend yield
52W range
$2 – $6
Volume
1.3M

Annovis Bio Inc (ANVS) Financial statements

SEC filings — annual and quarterly data.

Cash flow — annual

Item2009201020112012201720182019202020212022202320242025
Operating cash flow$-389230.00$-1.77M$-3.01M$-1.41M$-537481.00$-558609.00$-476542.00$-3.97M$-9.13M$-17.31M$-39.97M$-21.89B$-25.62B
Capital expenditures$5160.00$155870.00$79604.00$79604.00$0.00$0.00$0.00$3.00$0.00$4.00$4.00$4.00$0.00
Depreciation
Stock-based comp$48495.00$82728.00$8483.00$1.86M$4.70M$9.15M$4.63M$3.84B$1.80B
Free cash flow$-394390.00$-1.93M$-3.09M$-1.49M$-537481.00$-558609.00$-476542.00$-3.97M$-9.13M$-17.31M$-39.97M$-21.89B$-25.62B
Investing cash flow
Financing cash flow
Dividends paid
Share repurchases
Debt repayment
Net change in cash$8.07M$37.61M

Frequently asked questions

How much free cash flow does ANVS generate?

ANVS produced $-25.62B in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is ANVS's balance sheet healthy?

ANVS holds $19.53M in cash and equivalents against — in long-term debt, on $16.85M of shareholder equity. That debt is best read against the cash flow the business throws off each year.